Last reviewed · How we verify
anti IL5 receptor antibodies
Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation.
Anti-IL-5 receptor antibodies block the interleukin-5 receptor on eosinophils, preventing eosinophil activation and reducing eosinophilic inflammation. Used for Eosinophilic asthma, Chronic rhinosinusitis with nasal polyps, Eosinophilic granulomatosis with polyangiitis (EGPA).
At a glance
| Generic name | anti IL5 receptor antibodies |
|---|---|
| Sponsor | Scarlata, Simone, M.D. |
| Drug class | IL-5 receptor antagonist monoclonal antibody |
| Target | IL-5 receptor (IL-5R) |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
These monoclonal antibodies bind to the IL-5 receptor (IL-5R) on the surface of eosinophils and their precursors, blocking the signaling pathway that promotes eosinophil survival, activation, and recruitment. By inhibiting IL-5 signaling, these antibodies reduce circulating and tissue eosinophil counts, thereby suppressing eosinophil-mediated inflammatory responses in conditions characterized by eosinophilic inflammation.
Approved indications
- Eosinophilic asthma
- Chronic rhinosinusitis with nasal polyps
- Eosinophilic granulomatosis with polyangiitis (EGPA)
Common side effects
- Headache
- Injection site reactions
- Upper respiratory tract infections
- Arthralgia
Key clinical trials
- Benralizumab in the Treatment of Patients With Severe Asthma With ABPA (PHASE4)
- Flow Cytometry Analysis of Eosinophils in Severe Asthma Patients. (PHASE4)
- A Phase 2 Study to Evaluate the Safety and Efficacy of Intravenously Administered Benralizumab (MEDI-563). (PHASE2)
- Effects of Anti-IL5 Biological Treatments on Blood IgE Levels in Severe Asthmatic Patients
- A Phase 2a Study to Evaluate the Safety and Tolerability of Benralizumab (MEDI-563) in Adults With Asthma (PHASE2)
- A Study to Evaluate the Safety, Tolerability and Effects of MEDI-563 in Adults With Asthma (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- anti IL5 receptor antibodies CI brief — competitive landscape report
- anti IL5 receptor antibodies updates RSS · CI watch RSS
- Scarlata, Simone, M.D. portfolio CI